Alternative Therapeutic Approaches to Chronic Proton Pump Inhibitor Treatment

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 4, 2012, Pages 338-345

  Fass, Ronnie ^a  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Anti reflux medications; GERD; Heartburn

Indexed keywords

ALGINIC ACID; ALUMINUM; AMINOBUTYRIC ACID DERIVATIVE; ANTACID AGENT; BACLOFEN; BICARBONATE; CALCIUM CARBONATE; CANNABINOID RECEPTOR AGONIST; CITRATE SODIUM; DOMPERIDONE; GAVISCON; HISTAMINE H2 RECEPTOR ANTAGONIST; ITOPRIDE; MAGNESIUM HYDROXIDE; METABOTROPIC RECEPTOR ANTAGONIST; METOCLOPRAMIDE; MOSAPRIDE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; SEROTONIN 4 AGONIST; SUCRALFATE;

ACUPRESSURE; ACUPUNCTURE; ANTIREFLUX OPERATION; CLINICAL PRACTICE; CONSTIPATION; DIARRHEA; DRUG TREATMENT FAILURE; ENDOSCOPIC THERAPY; EVIDENCE BASED PRACTICE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LIFESTYLE MODIFICATION; LOWER ESOPHAGUS SPHINCTER; MEDICAL EDUCATION; NON EROSIVE REFLUX DISEASE; PATIENT COMPLIANCE; PHYSICIAN; PRESCRIPTION; PSYCHOTHERAPY; REFLUX ESOPHAGITIS; REVIEW; TREATMENT DURATION;

GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMP INHIBITORS; SURGICAL PROCEDURES, OPERATIVE;

EID: 84858699762     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.12.020     Document Type: Review

References (81)

1. Dent J., El-Serag H.B., Wallander M.A., et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005, 54:710-717.
2. Locke G.R., Talley N.J., Fett S.L., et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997, 112:1448-1456.
3. Nebel O.T., Fornes M.F., Castell D.O. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976, 21:953-956.
4. Sandler R.S., Everhart J.E., Donowitz M., et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002, 122:1500-1511.
5. Targownik L.E., Metge C., Roos L., et al. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol 2007, 102:942-950.
6. Chey W.D., Mody R.R., Wu E.Q., et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin 2009, 25:1869-1878.
7. Hershcovici T., Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr Opin Gastroenterol 2010, 26:367-378.
8. The Gallup Organization. The 2000 Gallup study of consumers' use of stomach relief products, 2000.
9. Yang Y.X., Metz D.C. Safety of proton pump inhibitor exposure. Gastroenterology 2010, 139:1115-1127.
10. Keszthelyi D., Jansen S.V., Schouten G.A., et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther 2010, 32:1124-1128.
11. Lombardo L., Foti M., Ruggia O., et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010, 8:504-508.
12. Bhatt D.L., Cryer B.L., Contant C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010, 363:1909-1917.
13. Laine L., Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction?. Am J Gastroenterol 2010, 105:34-41.
14. McColl K.E. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009, 104(Suppl 2):S5-S9.
15. Dial S., Alrasadi K., Manoukian C., et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004, 171:33-38.
16. Laheij R.J., Sturkenboom M.C., Hassing R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955-1960.
17. Richter J.E., Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD study group. Am J Gastroenterol 2000, 95:3071-3080.
18. Bardhan K.D., Hawkey C.J., Long R.G., et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther 1995, 9:145-151.
19. Castell D.O., Richter J.E., Robinson M., et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996, 91:1749-1757.
20. Sharma V.K., Leontiadis G.I., Howden C.W. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001, 15:227-231.
21. Fass R., Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009, 58:295-309.
22. Fass R., Shapiro M., Dekel R., et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next?. Aliment Pharmacol Ther 2005, 22:79-94.
23. Martinez S.D., Malagon I., Garewal H.S., et al. Non-erosive reflux disease (NERD)-is it really just a mild form of gastroesophageal reflux disease (GERD)?. Gastroenterology 2001, 120(Suppl 1):A424.
24. Adachi K., Hashimoto T., Hamamoto N., et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 2003, 18:1392-1398.
25. Lind T., Havelund T., Carlsson R., et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997, 32:974-979.
26. Dean B.B., Gano A.D., Knight K., et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004, 2:656-664.
27. Bate C.M., Griffin S.M., Keeling P.W., et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996, 10:547-555.
28. Miner P., Orr W., Filippone J., et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002, 97:1332-1339.
29. Van Soest E.M., Siersema P.D., Dieleman J.P., et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006, 24:377-385.
30. Kaltenbach T., Crockett S., Gerson L.B. Are lifestyle measures effective in patients with gastroesophageal reflux disease?. An evidence-based approach. Arch Intern Med 2006, 166:965-971.
31. Weberg R., Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol 1989, 24:401-406.
32. Grove O., Bekker C., Jeppe-Hansen M.G., et al. Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial. Scand J Gastroenterol 1985, 20:457-461.
33. Hampson F.C., Farndale A., Strugala V., et al. Alginate rafts and their characterisation. Int J Pharm 2005, 294:137-147.
34. Simon B., Mueller P. Comparison of the effect of sucralfate and ranitidine in reflux esophagitis. Am J Med 1987, 83:43-47.
35. Hameeteman W., v d Boomgaard D.M., Dekker W., et al. Sucralfate versus cimetidine in reflux esophagitis. A single-blind multicenter study. J Clin Gastroenterol 1987, 9:390-394.
36. Laitinen S., Stahlberg M., Kairaluoma M.I., et al. Sucralfate and alginate/antacid in reflux esophagitis. Scand J Gastroenterol 1985, 20:229-232.
37. Simon B., Ravelli G.P., Goffin H. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996, 10:441-446.
38. Richter J.E. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther 2005, 22:749-757.
39. Fass R., Hixson L.J., Ciccolo M.L., et al. Contemporary medical therapy for gastroesophageal reflux disease. Am Fam Physician 1997, 55:205-212. 217-218.
40. Wolfe M.M., Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000, 118:S9-S31.
41. Wang W.H., Huang J.Q., Zheng G.F., et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005, 11:4067-4077.
42. Johnson N.J., Boyd E.J., Mills J.G., et al. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther 1989, 3:259-266.
43. Kahrilas P.J., Fennerty M.B., Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999, 94:92-97.
44. Venables T.L., Newland R.D., Patel A.C., et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997, 32:965-973.
45. Fujiwara Y., Higuchi K., Nebiki H., et al. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005, 21(Suppl 2):10-18.
46. Pappa K.A., Gooch W.M., Buaron K., et al. Low-dose ranitidine for the relief of heartburn. Aliment Pharmacol Ther 1999, 13:459-465.
47. Pappa K.A., Williams B.O., Payne J.E., et al. A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn. Aliment Pharmacol Ther 1999, 13:467-473.
48. Fackler W.K., Ours T.M., Vaezi M.F., et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002, 122:625-632.
49. Hershcovici T., Fass R. Transient lower oesophageal sphincter relaxation reducers-have we hit a brick wall?. Aliment Pharmacol Ther 2011, 33:1256-1257. author reply, 1257-1258.
50. Zhang Q., Lehmann A., Rigda R., et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002, 50:19-24.
51. Koek G.H., Sifrim D., Lerut T., et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003, 52:1397-1402.
52. Vela M.F., Tutuian R., Katz P.O., et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003, 17:243-251.
53. Kahrilas P.J., Shaheen N.J., Vaezi M.F., et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008, 135:1383-1391. 1391.e1-5.
54. Hershcovici T., Fass R. Nonerosive reflux disease (NERD)-an update. Neurogastroenterol Motil 2010, 16:8-21.
55. Juul-Hansen P., Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem?. Scand J Gastroenterol 2011, 46:398-405.
56. Bytzer P., Blum A., De Herdt D., et al. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004, 20:181-188.
57. Juul-Hansen P., Rydning A. On-demand requirements of patients with endoscopy-negative gastro-oesophageal reflux disease: H2-blocker vs. proton pump inhibitor. Aliment Pharmacol Ther 2009, 29:207-212.
58. Wiklund I., Bardhan K.D., Muller-Lissner S., et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol 1998, 30:19-27.
59. Fass R., Delemos B., Nazareno L., et al. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease-a double-blind, placebo-controlled, randomized study. Aliment Pharmacol Ther 2010, 31:950-960.
60. Pace F., Tonini M., Pallotta S., et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken "on-demand". Aliment Pharmacol Ther 2007, 26:195-204.
61. Gerson L.B., Robbins A.S., Garber A., et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000, 95:395-407.
62. Cadiere G.B., Buset M., Muls V., et al. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg 2008, 32:1676-1688.
63. Bell R.C., Freeman K.D. Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease. Surg Endosc 2011, 25:1975-1984.
64. Hoppo T., Immanuel A., Schuchert M., et al. Transoral incisionless fundoplication 2.0 procedure using EsophyX for gastroesophageal reflux disease. J Gastrointest Surg 2010, 14:1895-1901.
65. Kim M.S., Holloway R.H., Dent J., et al. Radiofrequency energy delivery to the gastric cardia inhibits triggering of transient lower esophageal sphincter relaxation and gastroesophageal reflux in dogs. Gastrointest Endosc 2003, 57:17-22.
66. Arts J., Sifrim D., Rutgeerts P., et al. Influence of radiofrequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophageal reflux disease. Dig Dis Sci 2007, 52:2170-2177.
67. Noar M.D., Lotfi-Emran S. Sustained improvement in symptoms of GERD and antisecretory drug use: 4-year follow-up of the Stretta procedure. Gastrointest Endosc 2007, 65:367-372.
68. Galmiche J.P., Hatlebakk J., Attwood S., et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011, 305:1969-1977.
69. del Genio G., Tolone S., del Genio F., et al. Total fundoplication controls acid and nonacid reflux: evaluation by pre- and postoperative 24-h pH-multichannel intraluminal impedance. Surg Endosc 2008, 22:2518-2523.
70. Kahrilas P.J. Surgical therapy for reflux disease. JAMA 2001, 285:2376-2378.
71. Schwartz M.P., Smout A.J. Review article: the endoscopic treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007, 26(Suppl 2):1-6.
72. Spechler S.J., Lee E., Ahnen D., et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001, 285:2331-2338.
73. DeVault K.R., Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999, 94:1434-1442.
74. Bonavina L., Saino G.I., Bona D., et al. Magnetic augmentation of the lower esophageal sphincter: results of a feasibility clinical trial. J Gastrointest Surg 2008, 12:2133-2140.
75. Bonavina L., DeMeester T., Fockens P., et al. Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one- and 2-year results of a feasibility trial. Ann Surg 2010, 252:857-862.
76. Zou D., Chen W.H., Iwakiri K., et al. Inhibition of transient lower esophageal sphincter relaxations by electrical acupoint stimulation. Am J Physiol Gastrointest Liver Physiol 2005, 289:G197-G201.
77. Dickman R., Schiff E., Holland A., et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007, 26:1333-1344.
78. Mizyed I., Fass S.S., Fass R. Review article: gastro-oesophageal reflux disease and psychological comorbidity. Aliment Pharmacol Ther 2009, 29:351-358.
79. Fass R., Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002, 51:885-892.
80. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007, 41:131-137.
81. Lee Y.C., Wang H.P., Chiu H.M., et al. Comparative analysis between psychological and endoscopic profiles in patients with gastroesophageal reflux disease: a prospective study based on screening endoscopy. J Gastroenterol Hepatol 2006, 21:798-804.